AI Predictions Dashboard

Multi-Agent Predictive Intelligence powered by SEC 8-K filings analysis. Real-time insights for pharmaceutical and biotech stocks.

17%
Avg Probability
Bearish
Market Sentiment
7
High Confidence
25
Active Predictions

Event Distribution

Filters:
Showing 25 of 25
PRGO
1%

Perrigo Company plc

Price unavailable
Bearish-29%
HighEARNINGS

Perrigo Company plc (PRGO) released financial results. Analysis indicates limited probability of success (1%) based on clinical profile and regulatory outlook.

BGNE
5%

BeiGene, Ltd.

Price unavailable
Bearish-27%
LowEARNINGS

BeiGene, Ltd. (BGNE) released financial results. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

IONS
5%

Ionis Pharmaceuticals, Inc.

Price unavailable
Bearish-27%
LowEARNINGS

Ionis Pharmaceuticals, Inc. (IONS) released financial results. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

ELAN
5%

Elanco Animal Health Inc.

Price unavailable
Bearish-27%
LowEARNINGS

Elanco Animal Health Inc. (ELAN) released financial results. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

BMRN
5%

BioMarin Pharmaceutical Inc.

Price unavailable
Bearish-27%
HighEARNINGS

BioMarin Pharmaceutical Inc. (BMRN) released financial results. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

GILD
5%

Gilead Sciences, Inc.

Price unavailable
Bearish-27%
HighM&A

Gilead Sciences, Inc. (GILD) released strategic transaction. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

HALO
5%

Halozyme Therapeutics, Inc.

Price unavailable
Bearish-27%
LowEARNINGS

Halozyme Therapeutics, Inc. (HALO) released financial results. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

VRTX
5%

Vertex Pharmaceuticals Incorporated

Price unavailable
Bearish-27%
LowEARNINGS

Vertex Pharmaceuticals Incorporated (VRTX) released financial results. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

MRNA
5%

Moderna, Inc.

Price unavailable
Bearish-27%
HighCLINICAL_TRIAL

Moderna, Inc. (MRNA) released clinical trial results. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

MRNA
5%

Moderna, Inc.

Price unavailable
Bearish-27%
LowEARNINGS

Moderna, Inc. (MRNA) released financial results. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

BMRN
5%

BioMarin Pharmaceutical Inc.

Price unavailable
Bearish-27%
HighM&A

BioMarin Pharmaceutical Inc. (BMRN) released strategic transaction. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

ALNY
5%

Alnylam Pharmaceuticals, Inc.

Price unavailable
Bearish-27%
LowEARNINGS

Alnylam Pharmaceuticals, Inc. (ALNY) released financial results. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

TEVA
5%

Teva Pharmaceutical Industries Ltd

Price unavailable
Bearish-27%
HighEARNINGS

Teva Pharmaceutical Industries Ltd (TEVA) released financial results. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

HALO
5%

Halozyme Therapeutics, Inc.

Price unavailable
Bearish-27%
LowEARNINGS

Halozyme Therapeutics, Inc. (HALO) released financial results. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

AMGN
5%

Amgen Inc.

Price unavailable
Bearish-27%
LowEARNINGS

Amgen Inc. (AMGN) released financial results. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

JAZZ
1%

Jazz Pharmaceuticals plc

Price unavailable
Bearish-29%
LowPIPELINE_UPDATE

Jazz Pharmaceuticals plc (JAZZ) released pipeline update. Analysis indicates limited probability of success (1%) based on clinical profile and regulatory outlook.

LLY
1%

Eli Lilly and Company

Price unavailable
Bearish-29%
HighEARNINGS

Eli Lilly and Company (LLY) released financial results. Analysis indicates limited probability of success (1%) based on clinical profile and regulatory outlook.

BMRN
5%

BioMarin Pharmaceutical Inc.

Price unavailable
Bearish-27%
LowCLINICAL_TRIAL

BioMarin Pharmaceutical Inc. (BMRN) released clinical trial results. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

REGN
75%

Regeneron Pharmaceuticals, Inc.

Price unavailable
Bullish+31%
MediumEARNINGS

Regeneron Pharmaceuticals, Inc. (REGN) released financial results. Analysis indicates high probability of success (75%) based on clinical profile and regulatory outlook.

MRK
55%

Merck & Co., Inc.

Price unavailable
Bullish+26%
LowEARNINGS

Merck & Co., Inc. (MRK) released financial results. Analysis indicates moderate probability of success (55%) based on clinical profile and regulatory outlook.

PFE
10%

Pfizer Inc.

Price unavailable
Neutral-11%
LowEARNINGS

Pfizer Inc. (PFE) released financial results. Analysis indicates limited probability of success (10%) based on clinical profile and regulatory outlook.

ABBV
65%

AbbVie Inc.

Price unavailable
Bullish+19%
MediumEARNINGS

AbbVie Inc. (ABBV) released financial results. Analysis indicates moderate probability of success (65%) based on clinical profile and regulatory outlook.

BMY
65%

Bristol-Myers Squibb Company

Price unavailable
Bullish+23%
MediumEARNINGS

Bristol-Myers Squibb Company (BMY) released financial results. Analysis indicates moderate probability of success (65%) based on clinical profile and regulatory outlook.

JNJ
70%

Johnson & Johnson

Price unavailable
Bullish+21%
MediumEARNINGS

Johnson & Johnson (JNJ) released financial results with an overall response rate of 45%. Analysis indicates high probability of success (70%) based on clinical profile and regulatory outlook.

BMRN
5%

BioMarin Pharmaceutical Inc.

Price unavailable
Bearish-27%
LowEARNINGS

BioMarin Pharmaceutical Inc. (BMRN) released financial results. Analysis indicates limited probability of success (5%) based on clinical profile and regulatory outlook.

Disclaimer: These AI-generated predictions are for informational purposes only and should not be considered financial advice. Always conduct your own research and consult with a licensed financial advisor before making investment decisions.